karppaus.info

Diabetes management company Virta Health announced today that the company will offer its service to employers and health plans at 100 percent risk — that is, customers will only pay if the company succeeds in its goal of reversing Type 2 diabetes and getting patients off of expensive diabetes medications.

Tuota vanhaa kiinalaista keisarien henkilääkärien tapaahan olen peräänkuuluttanut kaikille terveydenhuoltajille. Hyvä Virta!

Virta on ilmeisesti muutanut hinnoitteluaan niin, että jos ei tule tuloksia, ei tarvitse maksaakaan.

t. Kari

Virran Hallberg ja Westman mukana tutkimuksessa, jonka Amerikan lastenlääkäreiden yhdistyksen lehti Pediatrics valitsi vuoden 2018 artikkeliksi:

Key Highlights
-All five participants reported feeling much better on the Virta program. Common themes included increased energy and desire to be active, better sleep, and reduced hunger.

-All 5 participants lowered their A1C with the low-carb approach and Virta coaching. The largest A1C drop was 2.1%!

-Three of the five participants lost more than 20 lbs on the Virta program.

-Before starting Virta, four of the five participants were using diabetes medications. Three users have eliminated all diabetes medications and one has reduced insulin requirements by 78% (from 80 units per day to 18 units per day).

RESULTS: Significant changes from baseline to 2 years in the CCI group included: HbA1c (-12% from
7.7±0.1%); fasting glucose (-18% from 163.67±3.90 mg/dL); fasting insulin (-42% from 27.73±1.26 pmol
L-1); weight (-10% from 114.56±0.60 kg); systolic blood pressure (-4% from 131.7±0.9 mmHg); diastolic
blood pressure (-4% from 81.8±0.5 mmHg); triglycerides (-22% from 197.2±9.1 mg/dL); HDL-C (+19%
from 41.8±0.9 mg/dL), and liver alanine transaminase (-21% from 29.16±0.97 U/L). Spine bone mineral
density in the CCI group was unchanged. Glycemic control medication use (excluding metformin)
among CCI participants declined (from 56.9% to 26.8%, P=1.3x10-11) including prescribed insulin (
62%) and sulfonylureas (-100%). The UC group had no significant changes in these parameters
(except uric acid and anion gap) or diabetes medication use. There was also significant resolution of
diabetes (reversal, 53.5%; remission, 17.6%) in the CCI group but not in UC. All the reported
improvements had p-values <0.00012.
CONCLUSIONS: The CCI sustained long-term beneficial effects on multiple clinical markers of
diabetes and cardiometabolic health at 2 years while utilizing less medication. The intervention was
also effective in the resolution of diabetes and visceral obesity, with no adverse effect on bone health.